A 17-year retrospective study of institutional results for eye plaque brachytherapy of uveal melanoma using 125I, 103Pd, and 131Cs and historical perspective

Iodine-125 Brachytherapy for Uveal Melanoma: A Systematic Review of Radiation Dose

“…Fourteen studies were retrospective clinical chart reviews [14,15,22,23,24,25,26,27,28,29,30,31,32], and 1 was a prospective, randomized trial, the COMS trial [17]. One retrospective study included patients from the COMS trial [15].…”

Heterogeneous dose calculations for Collaborative Ocular Melanoma Study eye plaques using actual seed configurations and Task Group Report 43 formalism

“…Dose rate inside the eye, however, may be estimated with comparable accuracy. Moreover, the EP method overcomes three significant limitations of the Tufts, Dome, or Plaque Simulator methods: Dose rate calculations may be performed (1) using FDA-approved TPSs, including Varian Brachytherapy TPS; (2) for EPs loaded with sources other than 125 I Model 6711 and 103 Pd Model 200; and (3) for seed configurations different than standard COMS.…”

“…Brachytherapy treatment of ocular malignancies, including but not limited to uveal melanoma, is most commonly performed in North America with Collaborative Ocular Melanoma Study (COMS) eye plaques (EPs) (1). The COMS EPs are available in standard designs and sizes to accommodate a range of tumor dimensions (2).…”

BEDVH-A method for evaluating biologically effective dose volume histograms: Application to eye plaque brachytherapy implants

“…4 A variety of low-energy photon-emitting radionuclides have been used but with no apparent differences in clinical outcomes. 1,2,[5][6][7] Dale quantitatively evaluated the biologically effective dose (BED) of nonpermanent brachytherapy implants as a function of several parameters. 8 In the present study, a method was developed to assess the volumetric dependence of BED as a function of implant duration, radionuclide, and radiobiological parameters for the tumor and organs at risk (OARs).…”